|

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

RECRUITINGSponsored by Rehab Werida
Actively Recruiting
SponsorRehab Werida
Started2025-12-25
Est. completion2026-02-28
Eligibility
Age18 Years – 80 Years
View on ClinicalTrials.gov →

NCT07379788

Summary

This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).

Eligibility

Age: 18 Years – 80 Years
Inclusion Criteria:

* age ≥18 years;
* left ventricular ejection fraction (LVEF) \<50%;
* Presence of functional mitral regurgitation (mild, moderate, or severe) on transthoracic echocardiography; and
* stable sinus rhythm or controlled atrial fibrillation.

Exclusion Criteria:

* primary (degenerative or rheumatic) mitral valve disease,
* prior mitral valve surgery or transcatheter intervention,
* acute decompensated heart failure within four weeks,
* significant primary valvular disease other than FMR,
* severe renal impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m²),
* inadequate echocardiographic image quality.

Conditions2

Heart DiseaseHeart Failure

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.